BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Loading...
Loading...

oxy-guanidines Pages on BioPortfolio:

BioPortfolio - 3-Dimensional Pharmaceuticals Incorporated
Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. ...
http://www.bioportfolio.com/biocorporate/4-3-Dimensional_Pha...

BioPortfolio - 3-Dimensional Pharmaceuticals Incorporated - Profile
Sep 6;14(17):4553-5. (DOI Direct Link). • Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based ...
http://www.bioportfolio.com/biocorporate/4-3-Dimensional+Pha...

Results from other life science and pharmaceutical sites:

Oxyguanidines. Part 2: Discovery of a novel orally active thrombin ...
Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. ...
http://www.ncbi.nlm.nih.gov/pubmed/15203151...

Oxyguanidines. Part 2: Discovery of a novel orally...[Bioorg Med ...
PubMed is a service of the US National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for ...
http://view.ncbi.nlm.nih.gov/pubmed/15203151...

Oxyguanidines: application to non-peptidic phenyl-...[Bioorg Med ...
We report here a novel series non-peptidic phenyl-based, highly potent, highly selective and orally bioavailable thrombin inhibitors using oxyguanidines as ...
http://www.ncbi.nlm.nih.gov/pubmed/12668020...

American Chemical Society – 234th National Meeting Targeting ...
cyclic oxyguanidines were also synthesized, but displayed. no activity against iNOS. AZ-10397767 – a CXCR2/CCR2b antagonist. from AstraZeneca ...
http://www.biomedcentral.com/content/pdf/cd-832872.pdf...

Benzylamine-based selective and orally bioavailabl...[Bioorg Med ...
1999]; Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. ... 2003]; Oxyguanidines. Part 2: Discovery of a novel orally active
...
http://www.ncbi.nlm.nih.gov/pubmed/9873581...

BioPortfolio - 3-Dimensional Pharmaceuticals Incorporated - Profile
Sep 6;14(17):4553-5. (DOI Direct Link). • Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based ...
http://www.bioportfolio.com/biocorporate/4-3-Dimensional+Pha...

Studies towards the identification of potent, sele...[Bioorg Med ...
2003]; Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. ...
http://www.ncbi.nlm.nih.gov/pubmed/10201839...

Paper alert
Oxyguanidines: Application to non-peptidic phenyl-. based thrombin inhibitors. Tomczuk B, Lu T, Soll RM, Fedde C, Wang A, Murphy L,. Crysler C, Dasgupta M, ...
http://www.biomedcentral.com/content/pdf/cd-498573.pdf...

Google Custom Search

Search
  

  Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2008 - BioPortfolio Limited.